Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Sep 24 2025 | BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 Industry News Industry Read More Aug 30 2025 | Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial Industry News Industry Read More Aug 26 2025 | Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Industry News Industry Read More Aug 25 2025 | BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 Industry News Industry Read More Aug 7 2025 | Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Industry News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Sep 24 2025 | BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 Industry News Industry Read More
Aug 30 2025 | Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial Industry News Industry Read More
Aug 26 2025 | Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Industry News Industry Read More
Aug 25 2025 | BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 Industry News Industry Read More
Aug 7 2025 | Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Industry News Industry Read More
